Biomednewsbreaks - Transcode Therapeutics, Inc. (NASDAQ: RNAZ) Reports Positive Phase 1A Results For TTX-MC138 And Advances Program Toward Phase 2A

(MENAFN- Investor Brand Network) TransCode Therapeutics (NASDAQ: RNAZ) announced additional results from its Phase 1a dose-escalation trial evaluating TTX-MC138, an investigational microRNA-10b inhibitor for advanced cancer. The study met its primary safety endpoint, with no dose-limiting toxicities observed across 16 patients who received a total of 86 doses. The company reported durable disease stabilization in multiple patients, including three participants who remain on treatment after 14, 16 and 21 cycles, supporting advancement of TTX-MC138 into Phase 2a clinical development.

Among 14 evaluable patients, nine (64%) achieved stable disease lasting six months based on RECIST criteria. TransCode also reported pharmacokinetic data demonstrating drug bioavailability consistent with preclinical findings and highlighted a metastatic thyroid cancer patient who experienced a significant decline in thyroglobulin levels and has maintained stable disease for 12 months. The company said the results support selection of a recommended Phase 2a dose of 4.8 mg/kg and provide a rationale for continued clinical development in patients with limited treatment options.

To view the full press release, visit

About TransCode Therapeutics

TransCode Therapeutics is a clinical stage company pioneering immuno-oncology and RNA therapeutic treatments for high risk and advanced cancers. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.

NOTE TO INVESTORS: The latest news and updates relating to RNAZ are available in the company's newsroom at

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio IBN: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

MENAFN03062026000224011066ID1111207364